Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management

Journal of Clinical and Experimental Hepatology

Volumn 3, Issue 1, 2013, Pages 37-49

  Ramappa, Vidyasagar ^a   Aithal, Guruprasad P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Drug induced liver injury; Genetic; Hepatotoxicity; Pathogenesis; Tuberculosis

Indexed keywords

ACETYLCYSTEINE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2E1; DRUG METABOLITE; ETHAMBUTOL; GLUTATHIONE; ISONIAZID; PREGNANE X RECEPTOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AGE; ALCOHOL CONSUMPTION; CYTOCHROME P450 2E1 GENE; DRUG ABSORPTION; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; GENE; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER INJURY; MALNUTRITION; MIXED INFECTION; NONHUMAN; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT WITHDRAWAL; TUBERCULOSIS;

EID: 84875810348     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2012.12.001     Document Type: Review

References (116)

1. Global Tuberculosis Control: WHO Report 2011 2011, World Health Organisation, viii, 246 p.
2. Schaberg T., Rebhan K., Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996, 9:2026-2030.
3. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
4. Kumar R., Bhatia V., Khanal S., et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010, 51:1665-1674.
5. Devarbhavi H., Dierkhising R., Kremers W.K. Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 2010, 52:798-799. author reply 799-800.
6. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89:806-815.
7. Tostmann A., Boeree M.J., Aarnoutse R.E., et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008, 23:192-202.
8. Mitchell J.R., Zimmerman H.J., Ishak K.G., et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976, 84:181-192.
9. Scharer L., Smith J.P. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969, 71:1113-1120.
10. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002, 22:145-155.
11. Fountain F.F., Tolley E., Chrisman C.R., et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005, 128:116-123.
12. Kopanoff D.E., Snider D.E., Caras G.J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978, 117:991-1001.
13. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982, 60:555-564. International Union Against Tuberculosis Committee on Prophylaxis.
14. Acharya S.K., Dasarathy S., Kumer T.L., et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996, 23:1448-1455.
15. Singh J., Garg P.K., Tandon R.K. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996, 22:211-214.
16. Millard P.S., Wilcosky T.C., Reade-Christopher S.J., et al. Isoniazid-related fatal hepatitis. West J Med 1996, 164:486-491.
17. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
18. Younossian A.B., Rochat T., Ketterer J.P., et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005, 26:462-464.
19. Papastavros T., Dolovich L.R., Holbrook A., et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002, 167:131-136.
20. Prince M.I., Burt A.D., Jones D.E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002, 50:436-439.
21. Ziakas P.D., Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009, 49:1883-1889.
22. Fountain F.F., Tolley E.A., Jacobs A.R., et al. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection. Am J Med Sci 2009, 337:317-320.
23. LoBue P.A., Moser K.S. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis 2005, 9:501-506.
24. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. J Am Med Assoc 1999, 281:1014-1018.
25. Snider D.E., Caras G.J. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992, 145:494-497.
26. Steele M.A., Burk R.F., DesPrez R.M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991, 99:465-471.
27. Chang K.C., Leung C.C., Yew W.W., et al. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?. Eur Respir J 2007, 29:347-351.
28. Yue J., Peng R.X., Yang J., et al. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 2004, 25:699-704.
29. Chowdhury A., Santra A., Bhattacharjee K., et al. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006, 45:117-126.
30. Olson H., Betton G., Robinson D., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000, 32:56-67.
31. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000, 356:1587-1591.
32. Scales M.D., Timbrell J.A. Studies on hydrazine hepatotoxicity. 1. Pathological findings. J Toxicol Environ Health 1982, 10:941-953.
33. Sarma G.R., Immanuel C., Kailasam S., et al. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986, 133:1072-1075.
34. Blum M., Grant D.M., McBride W., et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990, 9:193-203.
35. Hein D.W., Doll M.A., Rustan T.D., et al. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995, 55:3531-3536.
36. Huang Y.S., Chern H.D., Su W.J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889.
37. Wang P.Y., Xie S.Y., Hao Q., et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012, 16:589-595.
38. Huang Y.S., Chern H.D., Su W.J., et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37:924-930.
39. Bose P.D., Sarma M.P., Medhi S., et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011, 26:312-318.
40. Roy B., Chowdhury A., Kundu S., et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001, 16:1033-1037.
41. Leiro V., Fernandez-Villar A., Valverde D., et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008, 28:835-839.
42. Metushi I.G., Cai P., Zhu X., et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011, 89:911-914.
43. Nakajima A., Fukami T., Kobayashi Y., et al. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 2011, 82:1747-1756.
44. Jamis-Dow C.A., Katki A.G., Collins J.M., et al. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997, 27:1015-1024.
45. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharm 1978, 3:108-127.
46. Holdiness M.R. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharm 1984, 9:511-544.
47. Menzies D., Dion M.J., Rabinovitch B., et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004, 170:445-449.
48. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992, 145:36-41.
49. Nannelli A., Chirulli V., Longo V., et al. Expression and induction by rifampicin of CAR- and PXR-regulated CYP2B and CYP3A in liver, kidney and airways of pig. Toxicology 2008, 252:105-112.
50. Burk O., Koch I., Raucy J., et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004, 279:38379-38385.
51. Kimchi-Sarfaty C., Oh J.M., Kim I.W., et al. A " silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
52. Yimer G., Ueda N., Habtewold A., et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 2011, 6. e27810.
53. Byrne J.A., Strautnieks S.S., Mieli-Vergani G., et al. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002, 123:1649-1658.
54. Capelle P., Dhumeaux D., Mora M., et al. Effect of rifampicin on liver function in man. Gut 1972, 13:366-371.
55. Grosset J., Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983, 5(suppl 3):S440-S450.
56. Ellard G.A. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 1969, 50:144-158.
57. Lacroix C., Tranvouez J.L., Phan Hoang T., et al. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. Arzneimittelforschung 1990, 40:76-79.
58. Maffei Facino R., Carini M. The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450. Pharmacol Res Commun 1980, 12:523-537.
59. Shibata K., Fukuwatari T., Sugimoto E. Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats. Biosci Biotechnol Biochem 2001, 65:1339-1346.
60. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011, 66:1431-1446.
61. Labowitz J.K., Silverman W.B. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci 1997, 42:192-194.
62. Kahn J.B. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001, 47(suppl 3):32-37. discussion 44-48.
63. Wolfson J.S., Hooper D.C. Overview of fluoroquinolone safety. Am J Med 1991, 91:153S-161S.
64. Coleman C.I., Spencer J.V., Chung J.O., et al. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002, 36:1162-1167.
65. Ho C.C., Chen Y.C., Hu F.C., et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 2009, 48:1526-1533.
66. Saigal S., Agarwal S.R., Nandeesh H.P., et al. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001, 16:1028-1032.
67. Yee D., Valiquette C., Pelletier M., et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003, 167:1472-1477.
68. Pande J.N., Singh S.P., Khilnani G.C., et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996, 51:132-136.
69. Hwang S.J., Wu J.C., Lee C.N., et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997, 12:87-91.
70. Dossing M., Wilcke J.T., Askgaard D.S., et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996, 77:335-340.
71. Teleman M.D., Chee C.B., Earnest A., et al. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002, 6:699-705.
72. Shakya R., Rao B.S., Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004, 38:1074-1079.
73. Lee A.M., Mennone J.Z., Jones R.C., et al. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002, 6:995-1000.
74. Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992, 44:275-283.
75. Franks A.L., Binkin N.J., Snider D.E., et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989, 104:151-155.
76. Singla R., Sharma S.K., Mohan A., et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010, 132:81-86.
77. Warmelink I., ten Hacken N.H., van der Werf T.S., et al. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 2011, 105:400-408.
78. Buchanan N., Eyberg C., Davis M.D. Isoniazid pharmacokinetics in kwashiorkor. S Afr Med J 1979, 56:299-300.
79. Walter-Sack I., Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharm 1996, 31:47-64.
80. Fernandez-Villar A., Sopena B., Fernandez-Villar J., et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004, 8:1499-1505.
81. Sharma S.K., Balamurugan A., Saha P.K., et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166:916-919.
82. Tost J.R., Vidal R., Cayla J., et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005, 9:534-540.
83. White M.C., Tulsky J.P., Lee J.R., et al. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care 2012, 18:131-142.
84. Polesky A., Farber H.W., Gottlieb D.J., et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996, 154:1473-1477.
85. Pirmohamed M., Naisbitt D.J., Gordon F., et al. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 2002, 181-182:55-63.
86. Wang J.Y., Liu C.H., Hu F.C., et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011, 62:448-455.
87. Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998, 157:1871-1876.
88. Dworkin M.S., Adams M.R., Cohn D.L., et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005, 39:464-470.
89. Hustert E., Zibat A., Presecan-Siedel E., et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001, 29:1454-1459.
90. Nanashima K., Mawatari T., Tahara N., et al. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinb) 2012, 92:253-259.
91. Boelsterli U.A., Lim P.L. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity?. Toxicol Appl Pharmacol 2007, 220:92-107.
92. Huang Y.S., Su W.J., Huang Y.H., et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007, 47:128-134.
93. Martinez E., Collazos J., Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999, 78:361-369.
94. Covic A., Goldsmith D.J., Segall L., et al. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant 1998, 13:924-929.
95. Knobel B., Buyanowsky G., Dan M., et al. Pyrazinamide-induced granulomatous hepatitis. J Clin Gastroenterol 1997, 24:264-266.
96. Aithal G.P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin Drug Saf 2004, 3:519-523.
97. Murata K., Hamada M., Sugimoto K., et al. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives. J Hepatol 2007, 46:322-329.
98. Elsharkawy A.M. Todralazine hepatotoxicity: a sting in the histone tail. J Hepatol 2007, 46:189-192.
99. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998, 53:536-548.
100. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control; National Institute for Health and Clinical Excellence: Guidance, London 2011.
101. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:735-739.
102. Blumberg H.M., Burman W.J., Chaisson R.E., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
103. Treatment of Tuberculosis: Guidelines. 4th ed. WHO/HTM/TB/2009.420.
104. Peloquin C.A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62:2169-2183.
105. Magis-Escurra C., van Den Boogaard J., Ijdema D., et al. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 2012, 25:83-86.
106. Babalik A., Babalik A., Mannix S., et al. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011, 18:225-229.
107. Ormerod L.P., Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996, 77:37-42.
108. Burham P.C. Molecular basis for adaptive responses during chemically induced hepatotoxicity. Toxicol Sci 2006, 89:349-351.
109. Hunt C.M. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology 2010, 52:2216-2222.
110. Sharma S.K., Singla R., Sarda P., et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50:833-839.
111. Tahaoglu K., Atac G., Sevim T., et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001, 5:65-69.
112. Attri S., Rana S.V., Vaiphei K., et al. Isoniazid- and rifampicin-induced oxidative hepatic injury - protection by N-acetylcysteine. Hum Exp Toxicol 2000, 19:517-522.
113. Baniasadi S., Eftekhari P., Tabarsi P., et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010, 22:1235-1238.
114. Adhvaryu M.R., Reddy N., Vakharia B.C. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol 2008, 14:4753-4762.
115. Pirmohamed M., Aithal G.P., Behr E., et al. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011, 89:784-785.
116. Aithal G.P., Daly A.K. Preempting and preventing drug-induced liver injury. Nat Genet 2010, 42:650-651.